Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone induction therapy in newly diagnosed multiple myel...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Haematologica
Main Authors: Merz, Maximilian, Salwender, Hans, Haenel, Mathias, Mai, Elias K., Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W., Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Hillengass, Jens, Raab, Marc S., Schurich, Baerbel, Munder, Markus, Schmidt-Wolf, Ingo G.H., Gerecke, Christian, Lindemann, Hans-Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan, Goldschmidt, Hartmut
Formato: Artigo
Idioma:Inglês
Publicado: Ferrata Storti Foundation 2015
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4486231/
https://ncbi.nlm.nih.gov/pubmed/25840597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.124347
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares